JOURNAL REVIEWED: Orbit
Latest Contribution
Oxymetazoline hydrochloride for improved symmetry in Graves’ disease
Oxymetazoline hydrochloride 0.1% ophthalmic solution has Food & Drug Administration (FDA) approval for use in involution ptosis. It is an alpha 1 agonist and partial alpha 2 agonist that stimulates Muller’s muscle to lift the lid. The authors of this...
Congenital nasolacrimal duct obstruction in trisomy 21 vs non-trisomy 21 patients
This is a retrospective case review study looking at patients who underwent intervention for congenital nasolacrimal duct obstruction (CNLDO) between January 2017 and January 2018. The authors state that patients were excluded if there was less than 60 months of...
Congenital nasolacrimal duct obstruction in patients with craniofacial abnormalities
This is a retrospective study including 1998 patients over a period of 10 years. Of this number, 41 patients were identified as having a craniofacial abnormality and congenital nasolacrimal duct obstruction (CNLDO) (23.1 per 10,000 live births). Interestingly the most...
